HEMOSTEMIX INC - HMTXF STOCK NEWS

Hemostemix has announced an update to its second closing, adding a $50,000 subscription to reach total gross proceeds of $2,725,981.77 through the issuance of 54,519,635 Units. The company paid finder fees of approximately $28,820.64 and issued 576,413 finder's options exercisable at $0.05 per Common Share within 24 months.

The offering includes participation from company directors, constituting a related party transaction under MI 61-101. The company is exempt from formal valuation and minority shareholder approval requirements as the transaction value does not exceed 25% of market capitalization. All securities issued will have a four-month hold period from the closing date.

Hemostemix has completed its second and final tranche of private placement, raising $833,258 through the issuance of 16,665,160 Units at $0.05 per Unit. The combined offerings totaled $2,675,981.77 with 53,519,635 Units issued. Each Unit includes one common share and one warrant exercisable at $0.12 per share for 24 months. The proceeds will fund the company's stem cell therapeutics platform, initiate ACP sales, and cover operational expenses. The company paid approximately $24,820.64 in finder fees and issued 496,413 finder's options.

Hemostemix announces the launch of a social media campaign to promote and sell ACP-01 treatments under special access programs for various cardiovascular conditions. ACP-01, proven safe in 498 treatments across six clinical trials and one retrospective study with 318 subjects, has shown significant results. Notable outcomes include up to 47.1% improvement in cardiac function for dilated cardiomyopathy patients and 83% healing rate in CLTI patients. Recent CIHI data reveals concerning statistics about diabetes-related amputations, including 7,720 hospitalizations for lower limb amputations, with average hospitalization costs of $47,000 and annual costs reaching $750 Million.

Hemostemix has closed the first tranche of its private placement, raising $1.8 million through the issuance of 36.8 million Units at $0.05 per Unit. Each Unit includes one common share and one warrant exercisable at $0.12 for 24 months. The company paid finder fees of $88,660 and issued 1.7 million finder's options. Additionally, the company granted 3.7 million stock options to directors, officers, employees, and consultants at $0.10 per share, expiring October 31, 2029. The company will also issue 4.1 million shares at $0.10 per share to satisfy $408,547 in convertible debenture interest.

Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) has announced a private placement to raise up to $4,000,000 through the sale of Common Shares and Units at $0.05 each. Each Unit comprises one Common Share and one Warrant, allowing the holder to acquire an additional Common Share at $0.12 within 24 months of closing. The Warrants include an accelerated expiry provision if the stock price reaches or exceeds $0.15 for 10 consecutive trading days after four months from closing.

The company may involve directors in the private placement, which would be considered a 'related party transaction' under MI 61-101. Hemostemix is utilizing exemptions from formal valuation and minority shareholder approval requirements. All securities issued will be subject to a four-month hold period from the closing date.

Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) has signed a funded Manufacturing Services Agreement with CytoImmune Therapeutics to restart production of ACP-01, a stem cell therapy for cardiovascular diseases. The agreement is funded by issuing 30,140,000 common shares of Hemostemix at $0.05 each to CytoImmune. It covers the production of the first 22 ACP-01 therapies, which Hemostemix will sell for $1,100,000 ($50,000 each).

The companies aim to produce the first ACP-01 therapy by Q1 2025. Hemostemix expects to generate substantial cash flow from treating 480 no-option patients annually. The company is also closing a private placement of up to $2,000,000 from the sale of 40 Million Units at $0.05 each, with proceeds used for sales, marketing, and working capital.

Hemostemix announced it has been granted the trademark 'Your Fountain of Youth' by the Swiss Trademark Office, a significant milestone for the company's intellectual property portfolio.

CEO Thomas Smeenk highlighted the positive results from ACP-01, their cardiovascular treatment, with a 27% improvement in LVEF% and notable reductions in ulcer size, amputation, and mortality rates in clinical trials.

Additionally, Hemostemix will make a 2023 interest payment of $226,688.25 to debenture holders via 2,229,616 shares at $0.101671 per share, subject to regulatory approval and a four-month hold period under Canadian securities laws.

Hemostemix announced a strategic partnership with CytoImmune Therapeutics to re-establish ACP-01 production at CytoImmune's facility in Puerto Rico. The company secured $1,800,000 in financing commitments through a private placement at $0.05 per unit. CytoImmune will subscribe for $1,370,000 worth of these units. The partnership aims to scale production of ACP-01, a treatment for chronic limb-threatening ischemia (CLTI), potentially reaching sales of $2 million per month by 2025. Hemostemix's phase II clinical trial showed promising results, with 83% of patients experiencing ulcer healing and pain cessation. The proceeds of the financing will be used for initial batch processing and working capital.